CVS Health has launched Cordavis, a subsidiary that will work with manufacturers to commercialise and/or co-produce biosimilars for the US market. Cordavis has a contract with Sandoz to commercialize and bring to market Hyrimoz® (adalimumab), biosimilar to AbbVie’s Humira®, in Q1 of 2024 under a Cordavis private label. The list price of the Cordavis Hyrimoz® will be more than 80% lower than the current list price of Humira®.
On 1 July 2023, seven biosimilars to AbbVie’s Humira® (adalimumab), including Sandoz’s Hyrimoz® launched in the US. Sandoz announced its global adalimumab settlement with AbbVie on 11 October 2018.